Search

Displaying results 5361 - 5370 of 10000 in total
  1. Drug

    Egaptivon pegol

    go.drugbank.com/drugs/DB05202
    Investigational

    Egaptivon pegol, formerly known as ARC1779, is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor glycoprotein 1b on platelets. … Egaptivon pegol is being investigated for the treatment of thrombotic thrombocytopenic purpura and acute coronary syndromes.

  2. Drug

    Tyrosinase

    go.drugbank.com/drugs/DB16626
    Investigational

    [A231829, A231834, A231839] It is responsible for producing melanin pigment across the phylogenetic spectrum. … [A231829, A231834, A231839] Within mammals, tyrosinase is found specifically in melanocytes in a glycosylated form and plays a critical role in regulating the process of melanin biosynthesis (also known

  3. Drug

    UCB7362

    go.drugbank.com/drugs/DB17096
    Experimental

    [A254232] UCB7362 is estimated to achieve a significant reduction in asexual blood-stage parasites. … UCB7362 is an orally active plasmepsin X (PMX) inhibitor currently investigated for the treatment of malaria.

  4. Drug

    Promestriene

    go.drugbank.com/drugs/DB12487
    Investigational

    It is a synthetic estrogen analog, which is used in topical estrogen therapy. … The concern with absorbed vaginal estrogens or estrogen analogs is that they activate occult sites of residual breast cancer or negate the tumor suppressive effects of aromatase inhibitor adjuvant therapy

  5. Drug

    Efalizumab

    go.drugbank.com/drugs/DB00095
    ApprovedWithdrawn

    Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. … It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy (PML).[L43797]

  6. Drug

    Olcegepant

    go.drugbank.com/drugs/DB04869
    Investigational

    Boehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP) antagonist, a new class of drugs in development for the treatment of acute migraine attacks … Olcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential new approach to the treatment of migraine.

  7. Drug

    7-[(3-CHLOROBENZYL)OXY]-2-OXO-2H-CHROMENE-4-CARBALDEHYDE

    go.drugbank.com/drugs/DB07512
    Experimental

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  8. Drug

    Thymectacin

    go.drugbank.com/drugs/DB05116
    Investigational

    Thymectacin was as efficacious as irinotecan, a drug recently approved for the treatment of 5-fluorouracil-resistant colon cancer. … Thymectacin, a phosphoramidate derivative of (E)-5-(2-bromovinyl)-2'-deoxyuridine, is a novel small molecule anticancer agent.

  9. Drug

    Metisazone

    go.drugbank.com/drugs/DB13641
    Experimental

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  10. Drug

    Dihydroergocristine

    go.drugbank.com/drugs/DB13345
    Approved

    [L2637] It is a semisynthetic ergot alkaloid and thus, it is characterized by a structural skeleton formed by an alkaloid ergoline.

    Categories: Heterocyclic Compounds with 4 or More Rings